ADMA Biologics/$ADMA
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Ticker
$ADMA
Sector
Primary listing
Employees
644
Headquarters
Website
ADMA Biologics Metrics
BasicAdvanced
$1.8bn
11.60
$0.68
0.82
-
Price and volume
Market cap
$1.8bn
Beta
0.82
52-week high
$22.37
52-week low
$7.21
Average daily volume
7.3m
Financial strength
Current ratio
6.951
Quick ratio
3.726
Long term debt to equity
51.226
Total debt to equity
52.368
Interest coverage (TTM)
28.59%
Profitability
EBITDA (TTM)
214.822
Gross margin (TTM)
61.27%
Net profit margin (TTM)
32.43%
Operating margin (TTM)
40.57%
Effective tax rate (TTM)
19.86%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
21.99%
Return on equity (TTM)
43.30%
Valuation
Price to earnings (TTM)
11.596
Price to revenue (TTM)
3.676
Price to book
4.69
Price to tangible book (TTM)
4.74
Price to free cash flow (TTM)
17.428
Free cash flow yield (TTM)
5.74%
Free cash flow per share (TTM)
0.452
Growth
Revenue change (TTM)
10.99%
Earnings per share change (TTM)
-18.75%
3-year revenue growth (CAGR)
41.00%
10-year revenue growth (CAGR)
51.90%
3-year earnings per share growth (CAGR)
42.81%
10-year earnings per share growth (CAGR)
-9.21%
What the Analysts think about ADMA Biologics
Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.
ADMA Biologics Financial Performance
Revenues and expenses
ADMA Biologics Earnings Performance
Company profitability
ADMA Biologics News
AllArticlesVideos
ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation
Newsfile Corp·1 day ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
Newsfile Corp·4 days ago
ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors
Newsfile Corp·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ADMA Biologics stock?
ADMA Biologics (ADMA) has a market cap of $1.8B as of May 12, 2026.
What is the P/E ratio for ADMA Biologics stock?
The price to earnings (P/E) ratio for ADMA Biologics (ADMA) stock is 11.6 as of May 12, 2026.
Does ADMA Biologics stock pay dividends?
No, ADMA Biologics (ADMA) stock does not pay dividends to its shareholders as of May 12, 2026.
When is the next ADMA Biologics dividend payment date?
ADMA Biologics (ADMA) stock does not pay dividends to its shareholders.
What is the beta indicator for ADMA Biologics?
ADMA Biologics (ADMA) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.